Clinical Trial Update: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating SPD489 in adults with schizophrenia and predominant negative symptoms; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Schizophrenia with Predominantly Negative Symptoms

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: Schizophrenia and Predominant Negative Symptoms | Phase 2 | Status: COMPLETED | Results posted: 2012-02-20